
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suspension containing levofloxacin hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing levofloxacin are listed in tablet, injection and solution forms. No finished levofloxacin product of any kind is listed in suspension form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Levofloxacin is a fluoroquinolone antibiotic that a pharmacy may compound into other dosage forms when a prescriber orders it.
Levofloxacin is a fluoroquinolone antibiotic, the active L-isomer of ofloxacin. It kills bacteria by blocking DNA gyrase and topoisomerase IV, enzymes bacteria need to copy and repair their DNA. The original brand, Levaquin, is no longer marketed; generic tablets, oral solution, intravenous injection and ophthalmic drops are manufactured. Levofloxacin tablet labels list treatment of pneumonia, skin infections, chronic bacterial prostatitis, urinary tract and kidney infections, flares of chronic bronchitis and sinusitis, plus post-exposure inhalational anthrax and plague, in adults and in children where indicated. Because of serious risks, the label reserves it for uncomplicated urinary tract infection, bronchitis flares and sinusitis only when no other options exist. A prescriber might order it compounded in a strength or form that is not manufactured, or without a specific excipient. Compounded preparations are not FDA-approved and require a prescription.
Levofloxacin carries a boxed warning: fluoroquinolones have been linked to disabling and potentially irreversible serious reactions that can occur together, including tendinitis and tendon rupture, peripheral neuropathy and central nervous system effects, and they can worsen muscle weakness in myasthenia gravis. Other label warnings include serious allergic reactions, liver injury, aortic aneurysm and dissection, C. difficile diarrhea, QT prolongation, low or high blood sugar, and sun sensitivity. Tendon risk is higher after age 60, with corticosteroids, and after organ transplant. Do not take it if you are allergic to any quinolone. Separate antacids, iron, zinc, sucralfate and multivitamins by at least two hours; warfarin and diabetes medicines need closer monitoring. No drug-associated birth defect risk was found; the label and LactMed differ on breastfeeding. Stop it and contact your prescriber or pharmacist right away for tendon pain, numbness or tingling, or mood or behavior changes.
Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV. Oral absolute bioavailability is approximately 99 percent with peaks at one to two hours, serum protein binding is about 24 to 38 percent, and it is excreted largely unchanged in urine with a terminal half-life of about 6 to 8 hours, prolonged in renal impairment. Labeled indications for levofloxacin tablets (Lupin) include nosocomial and community-acquired pneumonia, skin and skin structure infections, chronic bacterial prostatitis, post-exposure inhalational anthrax, plague, complicated and uncomplicated urinary tract infection, acute pyelonephritis, acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis; StatPearls notes an ophthalmic formulation for bacterial conjunctivitis. StatPearls lists diabetic foot infection and osteomyelitis as off-label uses; these are not FDA-approved indications. Avoid in myasthenia gravis, known QT prolongation or uncorrected hypokalemia, use caution in older adults on corticosteroids, and adjust for renal function. Monitor glucose in diabetes and INR with warfarin. The label suggests pumping and discarding milk, or not breastfeeding, during treatment and for two days after, while LactMed considers it acceptable with infant monitoring. Dosing is per prescriber. Levofloxacin is not a controlled substance.
Shake the bottle well before every dose so the medication is evenly mixed. Measure with the oral syringe or dosing cup provided, using the milliliter markings, and never a kitchen spoon. Take it by mouth as your label directs. Rinse the syringe after use and recap the bottle.
Water-based suspensions are aqueous preparations. Under USP <795>, a preserved suspension usually carries a beyond-use date of up to 35 days at room temperature or refrigerated; an unpreserved one is refrigerated for up to 14 days. Oil-based suspensions are nonaqueous and may carry up to 90 days. Your label states storage and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally